These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 15919452

  • 1. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H, Okuyama K, Konno O, Jojima Y, Akashi I, Nakamura Y, Iwamoto H, Hama K, Iwahori T, Uchiyama M, Ashizawa T, Matsuno N, Nagao T, Hirano T, Oka K.
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y, Takeuchi H, Okuyama K, Akashi T, Jojima Y, Konno O, Akashi I, Hama K, Iwahori T, Ashizawa T, Hirano T, Oka K, Matsuno N, Nagao T.
    Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
    [Abstract] [Full Text] [Related]

  • 3. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H, Matsuno N, Hirano T, Toraishi T, Konno O, Nakamura Y, Iwamoto H, Hama K, Unezaki S, Nagao T.
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [Abstract] [Full Text] [Related]

  • 4. Evidence of different pharmacokinetics including relationship among AUC, peak, and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter--why cyclosporine is monitored by C(2) level and tacrolimus by trough level--.
    Takeuchi H, Matsuno N, Senuma K, Hirano T, Yokoyama T, Taira S, Kihara Y, Kuzuoka K, Konno O, Jojima Y, Mejit A, Akashi I, Nakamura Y, Iwamoto H, Hama K, Iwahori T, Ashizawa T, Nagao T, Toraishi T, Okuyama K, Oka K, Unezaki S.
    Biol Pharm Bull; 2008 Jan; 31(1):90-4. PubMed ID: 18175948
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
    [Abstract] [Full Text] [Related]

  • 6. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H, Jeffery J, Sitar DS, Aoki FY.
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [Abstract] [Full Text] [Related]

  • 7. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 8. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
    Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, Kuypers D, Le Meur Y, Marquet P, Oellerich M, Thervet E, Toenshoff B, Undre N, Weber LT, Westley IS, Mourad M.
    Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
    [Abstract] [Full Text] [Related]

  • 9. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F.
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [Abstract] [Full Text] [Related]

  • 10. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P, Shihab FS, Mulloy L, Henning AK, Gao J, Bartucci M, Holman J, First MR, OPTIMA Study Group.
    Transplantation; 2008 Jul 15; 86(1):88-95. PubMed ID: 18622283
    [Abstract] [Full Text] [Related]

  • 11. Circadian and time-dependent variability in tacrolimus pharmacokinetics.
    Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Tedesco-Silva H, Medina-Pestana JO.
    Fundam Clin Pharmacol; 2007 Apr 15; 21(2):191-7. PubMed ID: 17391292
    [Abstract] [Full Text] [Related]

  • 12. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial.
    Meier M, Nitschke M, Weidtmann B, Jabs WJ, Wong W, Suefke S, Steinhoff J, Fricke L.
    Transplantation; 2006 Apr 15; 81(7):1035-40. PubMed ID: 16612281
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation.
    Aidong W, Zhenjie C, Tong L, Lei Z, Yin W, Shanqi Z, Liping T.
    Transplant Proc; 2004 Oct 15; 36(8):2388-9. PubMed ID: 15561258
    [Abstract] [Full Text] [Related]

  • 14. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
    Meçule A, Tinti F, Poli L, Bachetoni A, Umbro I, Nofroni I, Lai Q, Pretagostini R, Berloco PB, Mitterhofer AP.
    Transplant Proc; 2011 May 15; 43(4):1024-7. PubMed ID: 21620042
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients.
    Lumlertgul D, Noppakun K, Rojanasthien N, Kanchanarattanakorn K, Jittikanont S, Manoyot A, Bunnachak D, Ophascharoensuk V.
    J Med Assoc Thai; 2006 Aug 15; 89 Suppl 2():S73-8. PubMed ID: 17044457
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
    Koefoed-Nielsen PB, Karamperis N, Jørgensen KA.
    Transplant Proc; 2005 May 15; 37(4):1736-8. PubMed ID: 15919449
    [Abstract] [Full Text] [Related]

  • 17. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor.
    Brandhorst G, Tenderich G, Zittermann A, Oezpeker C, Koerfer R, Oellerich M, Armstrong VW.
    Ther Drug Monit; 2008 Feb 15; 30(1):113-6. PubMed ID: 18223473
    [Abstract] [Full Text] [Related]

  • 18. Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients.
    Sugioka N, Kokuhu T, Okamoto M, Yoshimura N, Ito Y, Shibata N, Takada K.
    J Pharm Pharmacol; 2006 Sep 15; 58(9):1193-200. PubMed ID: 16945177
    [Abstract] [Full Text] [Related]

  • 19. Increase in renal vascular resistance after intake of cyclosporin A and tacrolimus and reversal by nitroglycerin spray: a study in patients with stable renal allograft function.
    Weingart C, Leingärtner T, Bergler T, Krüger B, Böger C, Mack M, Banas B, Krämer BK.
    Int J Clin Pharmacol Ther; 2006 Sep 15; 44(9):422-7. PubMed ID: 16995330
    [Abstract] [Full Text] [Related]

  • 20. Randomized clinical trial of tacrolimus- vs cyclosporine-based immunosuppression in pediatric heart transplantation: preliminary results at 15-month follow-up.
    Pollock-Barziv SM, Dipchand AI, McCrindle BW, Nalli N, West LJ.
    J Heart Lung Transplant; 2005 Feb 15; 24(2):190-4. PubMed ID: 15701436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.